Travere Therapeutics Reports First Quarter 2025 Financial Results View Full Press Release Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy Travere Therapeutics to Participate at Upcoming Investor Conferences